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Abstract: Lower urinary tract symptoms (LUTS) caused by benign prostatic hyperplasia 
(BPH) will usually affect older men, of whom 50% over the age 60 years and almost 90% in 
their nineties will be bothered enough by their symptoms that they request some type of treat-
ment. However, symptomatic bother may also affect men in their forties with a prevalence rate 
of almost 18%. The International Prostate Symptom Score (IPSS) has become the most widely 
used and best validated questionnaire to allow the patient to quantify the severity of his LUTS/
BPH symptoms. This score has become the cornerstone in demonstrating the “rate of symptom 
response” for the patient who has been exposed to any type BPH management. Question 8 on 
the IPSS score is what is defined as the “Quality of Life” question or what is also termed the 
“Bothersome Index.” The score out of 6 as declared by the patient will reflect the degree of con-
cern that the patient is feeling about his symptoms and the reduction of the score after treatment 
is a statement of their improved quality of life. There are 2 families of accepted medical therapy 
to treat the symptoms of BPH and potentially prevent the most worrisome long-term sequelae 
of progression of BPH: urinary retention or the need for surgery. When defining the impact of 
the main types of medical therapy, the alpha blockers have been termed the “openers” and the 
5 alpha-reductase inhibitors are described as the “shrinkers.” Since they each offer a different 
mechanism of effect, the concept of combination therapy was raised and trialed many times 
over recent years. The final aspect of any medical therapy is the patient’s satisfaction with the 
treatment and the side effects. In the CombAT (Combination of Avodart and Tamsulosin) trial 
a new assessment was developed and tested called the Patient’s Perception of Study Medication 
(PPSM) which told the investigators if the patients, given free choice, would choose to take that 
combination of medication to treat their problem and stay on the medication.
Keywords: lower urinary tract symptoms, benign prostatic hyperplasia, Benign Prostatic 
  Hyperplasia Impact Index, combination therapy, alpha blockers, 5 alpha reductase inhibitors, 
quality of life, BII, Patient’s Perception of Study Medication
Introduction
For over 20 years men have been treated medically for the symptoms of what was always 
thought to arise from benign prostatic hyperplasia (BPH). Today we understand that 
the symptoms are more correctly termed lower urinary tract symptoms (LUTS). The 
bladder has 2 main functions, storage and voiding (emptying). The commonest cause 
for the man over the age of 50 years for LUTS is indeed BPH.
Many years ago, Barry et al developed what was to become the most widely 
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  symptoms. The International Prostate Symptom Score (IPSS) 
is a   quantification of the severity of symptoms as it is self-
reported by the patient.1 This has become the gold standard 
in establishing the baseline and then follow-up score after 
any type (medical, natural, or surgical) of intervention for the 
management of BPH. Each question of the first 7 could be 
classified as either a “voiding” or a “storage” question.
A score of:
0 is defined as NO symptoms
#7 is defined as MILD symptoms
$8 and #19 is defined as MODERATE symptoms
$19 and #35 is defined as SEVERE symptoms.
Barry also proved in clinical trials that a minimum of a 
3-point improvement on the symptom scale was necessary 
for the patient to perceive the clinical improvement.
Question 8 on the IPSS score is the Quality of Life 
  question or what is more aptly termed the “Bothersome 
Index.”
This key question is “If you were to spend the rest of your 
life with your urinary condition the way it is now, how would 
you feel about that?” A score of 0 equates to “delighted” and 
a score of 6 equates to “terrible.”
Again this is a self-reported declaration of the patient’s 
perceived bother from his symptoms after considering his 
ability to tolerate the present degree of symptoms for the 
rest of his life.
I also define question 8 as the “motivational index.” The 
higher the bothersome index, the more motivated the patient 
will be to accept the “risk/benefit” ratio discussion about 
the benefits of the proposed therapy balanced against the 
potential side effects of  the medication. Kirby et al also deter-
mined that the 3/6 is the cutpoint for the minimum number 
that the patient will report, which will indicate that he is 
willing to accept treatment for his symptoms.11
Another questionnaire used to measure quality of life 
(QoL) for BPH patients is called the BPH Impact Index 
(BII), which
•	 Assesses overall impact of BPH on a patient’s general 
sense of well-being
•	 Measures aspects of physical discomfort, worry, and 
bother, all of which can be affected by BPH and its 
symptoms
•	 BPH Impact Index:
1.  Over the past month how much physical discomfort 
did any urinary problems cause you?
2.  Over the past month, how much did you worry about 
your health because of any urinary problems?
3.  Overall, how bothersome has any trouble with 
  urination been during the past month?
4.  Over the past month, how much of the time has any 
urinary problem kept you from doing the kind of 
things you would usually do?
Total score from 0 to 13 (higher score = worse BPH-
related health status).2
It has been shown that BPH, if untreated, may progress. 
There are certain risk factors that will predict the progres-
sion of BPH/LUTS. Progression of BPH can have a dramatic 
impact on the patients well-being (Figure 1).
Physiology
There are two medical approaches to the management of 
BPH, which work through the different receptors within the 
bladder and the prostate.
The alpha blockers block the smooth muscle receptors 
at the bladder neck, in the bladder, and within the prostate, 
thereby relaxing the tension that “opens” the bladder neck 
allowing for easier, stronger flow and a more complete emp-
tying, which means less frequency, urgency, and nocturia. 
The response is very quick, in hours to a few days, but the 
long-term response is relatively short, where most men need 
an adjustment in dosage or movement to another therapy 
by 4 years. As was seen in the Medical Therapy of Prostate 
Symptoms (MTOPS) trial at 5.5 years, the alpha blocker 
doxozasin was able to provide better symptom response than 
the monotherapy of finasteride or placebo.8 However, alpha 
blockers do not prevent the progression of BPH, which usually 
culminates in urinary retention and/or the need for surgery.9
The 5 alpha reductase (5ARI) inhibitors work through a dif-
ferent mechanism. They prevent the conversion of testosterone 
to dihydrotestosterone (DHT). It is the DHT, when bound to 
the RNA in the cells of the prostate, that stimulate growth of 
the cells and glands within the prostate. After 3–6 months of 
therapy the cells and prostate that has been deprived of DHT 
will shrink. There are 2 5ARI iso-enzymes, type 1 and type 2. 
Finasteride will inhibit only the type 2 receptors whereas 
dutasteride will inhibit both type 1 and type 2. This extra 
inhibition results in a greater reduction of DHT of almost 95% 
Enlarged prostate size (>30 cc)
PSA (as a surrogate for prostate size) ≥ 1.5 ng/mL
Age > 50 years
Moderate IPSS symptoms (>8)
Figure 1 Risk factors for benign prostatic hyperplasia progression.3–7
Abbreviations: IPSS, International Prostate Symptom Score; PSA, prostate-specific 
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versus 71%.10 We do not yet know the exact minimum DHT 
threshold suppression to achieve maximum shrinkage of the 
gland through maximum and prolonged androgen receptor 
blockade within the prostate. The 5ARIs achieve a slow onset 
of response as demonstrated by the expected 6-month drop in 
the prostate-specific antigen (PSA), volume reduction of the 
gland, and the prevention of progression.
History of combination therapy
From the launch of the first alpha blocker and 5ARI in the 
early 1990s the concept of combination therapy was enter-
tained (Figure 2). The hypothesis was that the synergistic 
effect of the two drugs would provide the early onset of 
symptom response from the alpha blocker and the long-
term durability of symptom response and prevention of 
progression from the 5ARI. The concern was in the lack 
of knowledge as to whether there would also be synergy 
in the complications or side effects of the 2 drug families 
as well.
There were numerous trials, but the results of the early 
combination trials using finasteride and the non-selective 
alpha blockers (Predict:11 European – doxazosin and finas-
teride; Va-coop:12 American – terazosin and finasteride) 
were a disaster. The results showed that the finasteride 
monotherapy arm was no better than placebo when measur-
ing symptom response.
In retrospect the faults were that the studies were too 
short (only 1 year) and the prostate volumes may have 
been too small (,30 mL) to reap the benefits of the 5ARI 
finasteride.
Efficacy of long-term combination 
therapy
The first long-term combination trial, MTOPS, which was 
performed only in the United States on 3047 men with 
  moderate symptoms of BPH and a PSA , 4, lasted for 5.5 
years and compared monotherapy of doxozasin, finasteride, or 
placebo to the combination of doxozasin and finasteride.8
The results were very impressive in that they demonstrated 
a 67% risk reduction in progression of disease at 4.5 mean 
years of follow-up in the combination arm compared with 
placebo. There was an insignificant difference in the response 
in any of the arms compared with placebo at 1 year.
The same cohort also demonstrated a 66% risk reduction 
in developing acute urinary retention (AUR) or the need for 
surgery in the combination arm compared with placebo at 
study end.
An analysis of the response when the patients were strati-
fied by prostate volume revealed that a volume of 30 mL was 
the minimum necessary to derive a clinically significant 
response in the 5ARI arm whether monotherapy or combina-
tion compared with placebo.15
QoL was a secondary endpoint in MTOPS (assessed using 
the Medical Outcomes Study Short Form-36 Health Survey 
instrument). However, no QoL outcomes for combination 
therapy have been published from MTOPS.
Dutasteride monotherapy trials had been performed and 
reported in 2004 in which the long-term effects of dutat-
steride were compared with placebo. The results of the 4-year 
extended monotherapy trial showed an 80% better symptom 
response, 56% PSA reduction, 27% volume reduction, and a 
70% risk reduction in either AUR or the need for surgery.16
Tamsulosin had previously been recognized as a uroselec-
tive alpha blocker, which provided the maximum therapeutic 
effect while causing far less risk of cardiovascular side effects 
such as orthostatic hypotension, as was found in the non-
selective alpha blockers like doxazosin.17
It had already been shown that dutasteride was very 
effective compared with placebo in men with BPH, espe-
cially in those with large prostates (.30 mL). As well, 
as previously stated the risk factors for BPH progression 
as determined at time of diagnosis were age . 50 years, 
prostate volume . 30 mL, and moderate symptoms on the 
IPSS ($7).
Another recent consideration is the fact that it has been 
shown that the PSA in BPH can be a surrogate predictor of 
the prostate volume. One can virtually guarantee that if the 
PSA is .1.5 ng/mL, regardless of the age of the patient the 
actual prostate volume will be at least 30 mL.18
Consequently, the Combination of Avodart and Tamsu-
losin (CombAT) trial had different inclusion criteria from 
MTOPS, which were recognized as defining a more “at 
Finasteride
launched
1991
First alpha blocker13
for BPH launched
1990
PLESS14
1996–1998
Dutasteride
4-year data
2004
Dutasteride
launched
2002
Phase llla
dutasteride
2003
CombAT
2007–
PREDICT11
1999–2003
VA-COOP12
1996–1998
MTOPS8
2003–2006
Figure  2  Milestones  of  changes  in  medical  management  of  benign  prostatic 
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risk” population for BPH progression.20 The average   prostate 
  volume in all 3 arms at the baseline was 55 mL and the aver-
age PSA was 4.0.
Based on all of these considerations no ethical review 
board in any of the 32 countries felt comfortable in requesting 
a placebo arm for the 4 years of the trial knowing that this 
population, without treatment, had a great chance of progress-
ing, developing AUR, or needing surgery by the end of the 
trial. Therefore, only 3 arms were required: Monotherapy of 
Tamsulosin or Dutatsteride, compared with the combination 
arm of Dutatsteride and Tamsulosin.
There were other significant differences as well 
(Figure 3).
The protocol was designed such that there was both a 
2-year and 4-year analysis. The primary endpoint at the 
2-year mark was the change in the IPSS responders’ scores 
from baseline comparing combination to the active treatment 
of tamsulosin (MTOPS compared with placebo).
CombAT MTOPS
Treatment groups Dutasteride 0.5 mg
monotherapy
Finasteride 5 mg
monotherapy
Doxazosin 4 or 8 mg
monotherapy
Finasteride and doxazosin 
combination therapy
Placebo
Tamsulosin 0.4 mg
monotherapy
Dutasteride and tamsulosin
combination therapy
n
Location
Entry criteria
Primary endpoints
Age
4844
≥50 ≥50
≥30 PV (cc)
PSA (ng/mL)
IPSS
2-year
4-year
≥1.5 and ≤10
≥12
≤10
None
None
8–30
Improvement in IPSS
Reduction in risk of AUR or
surgery
Composite endpoint of BPH
clinical progression
3047
International US only
Figure 3 Comparison of baseline demographics and study designs of MTOPS and CombAT.19
Abbreviations: AUR, acute urinary retention; BPH, benign prostatic hyperplasia; IPSS, International Prostate Symptom Score; PV, prostate volume; PSA, prostate-specific 
antigen.
Note: Reprinted with permission from Roehrborn CG, Siami P, Barkin J, et al. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in 
men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol. 2010;57(1):123–131.19 Copyright © 2010 elsevier.
0.0
−1.0
−2.0
−3.0
−4.0
−5.0
−6.0
−7.0
−8.0
3
Combination (n = 1575) Dutasteride (n = 1592) Tamsulosin (n = 1582)
69
Study month
A
d
j
u
s
t
e
d
 
m
e
a
n
 
c
h
a
n
g
e
 
f
r
o
m
 
b
a
s
e
l
i
n
e
 
i
n
 
I
P
S
S
12 15 18 21 24 27 30 33 36 39
–6.5 –6.3 –6.3 –6.2 –6.2 –6.2 –6.0 –6.0
–5.6 –5.4
–6.4 –6.3 –6.3
–5.3 –5.4 –5.2 –5.2 –5.2 –5.1 –5.3
–4.9 –4.9 –4.8
–4.8
–4.2 –4.0
–3.4
P < 0.001 combination versus dutasteride
P < 0.001 combination versus tamsulosin
–2.8
–4.7
–4.4
–4.8 –4.8
–4.5
–4.5
–4.5 –4.4 –4.4
–4.1 –4.2 –4.0 –4.0
–3.8 –3.8 –3.8
–4.3
–5.0
–5.3
–6.4
42 45 48 Baseline
Figure 4 Mean change International Prostate Symptom Score (IPSS) from baseline: primary endpoint in 4-year CombAT trial.
Note: Reprinted with permission from Roehrborn CG, Siami P, Barkin J, et al. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in 
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There were many secondary endpoints, which included 
percent with a $25% change in IPSS, change in prostate 
volume, Qmax (peak uroflow rate) improvement in mL/second, 
BII, QoL as defined by question 8 in the IPSS as well as a 
newly developed assessment called the Patients Perception 
of Study Medication (PPSM).
In every endpoint measured at 2 years there was a sig-
nificant improvement in the combination arm compared with 
either monotherapy arm, with a consistently and statistically 
better response than the tamsulosin arm.22
This was the first combination trial ever where the 
response as measured by the IPSS score was better in the 
5ARI or combination arm than the alpha blocker. Until this 
study, it had always been reported when measuring symptom 
response, especially up to 4 years, that the alpha blocker 
would outperform the 5ARI. In MTOPS, when assessing 
IPSS response, doxozasin always achieved a lower IPSS 
score than finasteride even out to 5.5 years. In this study the 
crossover point where dutasteride monotherapy outperformed 
tamsulosin monotherapy occurred at 15 months and never 
reverted.19 Combination therapy surpassed tamsulosin in 
IPSS response as early as 3 months22 (Figure 4).
Acceptance
QoL improvement with combination 
therapy
The QoL responses were also very significant. It is the patient’s 
feeling of improvement that will encourage him to continue 
in the study. Barry et al had previously determined that a 1.1 
point improvement in question 8 or a 2-point improvement in 
the BII would be considered as a “marked” (slight, moderate, 
marked) clinical improvement and definitely perceived by the 
patient. Again the combination arm achieved both a clinically 
significant question 8 response compared with tamsulosin as 
early as 3 months (−1.4 vs −1.1) as well as the “marked” BII 
response (−2.1 vs −1.5) by the end of 2 years.23
Two other significant clinical responses were seen by the 
end of the 2 years. The first was that there was a 55% reduc-
tion from the baseline PSA in the dutasteride or combina-
tion arm and a 12.5% increase from the baseline PSA in the 
Primary
– Time to event/proportion of subjects with AUR 
or BPH-related surgery
Secondary
– Time to BPH-related clinical progression –
First of: 
– Symptom deterioration by IPSS  ≥ 4 points  
– Acute urinary retention 
– Incontinence
– Recurrent UTI or urosepsis  
– Renal insufficiency related to BPH 
Figure 5 Four-year primary and secondary CombAT endpoints.21
Abbreviations: AUR, acute urinary retention; BPH, benign prostatic hyperplasia; 
iPSS, international Prostate Symptom Score; UTi, urinary tract infection.
16
Higher incidence detected from
Month 8 in the tamsulosin arm versus
the combination or dutasteride
monotherapy arms
RRR for combination
versus tamsulosin = 65.8%
(95% CI: 54.7, 74.1%)
RRR for combination
versus dutasteride = 19.6%
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Figure 6 CombAT 4-year composite primary endpoint – time to first AUR or BPH surgery.
Note: Reprinted with permission from Roehrborn CG, Siami P, Barkin J, et al. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in 
men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol. 2010;57(1):123–131.19 Copyright © 2010 elsevier.
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tamsulosin arm. Also there was a 28% volume reduction in 
the dutasteride/tamsulosin combination arm, with no change 
or a slight increase from the baseline volume in the alpha 
blocker arm.
At 4 years the endpoints were more inclusive and the 
results even more significant (Figure 5). It is important to 
remember that these patients had average baseline volumes 
of 55 mL (proven by transrectal ultrasound measurements), 
average PSAs of 4.0, average IPSS score of 16.7 (almost in 
the “severe” range). Also all responses that were achieved 
were compared with the active treatment arm of tamsulosin, 
unlike MTOPS where the combination arm response was 
compared with placebo.
The most important consideration for a man who is 
at risk for BPH progression is the possibility that he will 
develop AUR or need surgery to correct the sequelae of his 
profound BPH.
The 4-year primary composite endpoint of AUR or the 
need for surgery achieved significant results20 (Figure 6).
The patients in the combination arm of dutasteride and 
tamsulosin enjoyed a 66% risk reduction for developing 
these devastating problems compared with those in the active 
treatment tamsulosin arm. In the MTOPS trial there was a 
67% risk reduction in these same endpoints, but in that case it 
was the combination of finasteride and doxozasin compared 
with placebo.8
All of the other secondary 4-year endpoints of   clinical 
progression also had a statistically better response in the com-
bination arm than either monotherapy arm19 (Figure 7).
The 4-year response as measured by the BII or question 
8 was maintained and actually increased compared with the 
2-year reported response. BII reached a −2.2 points, whereas 
question 8 achieved a −1.6 points, both of which were 
statistically significant compared with tamsulosin.24
PPSM
The new parameter that was developed and validated 
  specifically for this study was the PPSM (Figure 8). This 
was a questionnaire that tested the patient’s appreciation of 
the study medication and their ultimate desire, after weigh-
ing the risks (side effects actually experienced) against the 
clinical benefits achieved, would they voluntarily choose and 
be compliant in taking that medicine.
The absolute improved response in the combination arm 
compared with either dutasteride or tamsulosin was statisti-
cally significant (−7.0 vs −5.5 vs −4.1 out of a maximum of 
25, respectively).19
Even more important was the overall acceptance of the 
combination therapy compared with the monotherapy arms 
(Figure 9).
Safety and side effects
It was shown that the combination was very effective. The 
question about whether the incidence of side effects as 
Combination
(n = 1610)
Dutasteride
(n = 1623)
Tamsulosin
(n = 1611)
At Year 4% %%
12.6% 17.8%*
31.2%
(17.7%–42.5%) (33.6%–53.0%)
44.1%
5.1% 2.3%
3.7%
0.3% 0.3%
0.4%
4.0%
0.1%
21.5%*
8.6% 13.1%* 14.2%*
1.6%
3.0%
0.2%
<0.1%
Clinical progression
Risk reduction versus 
combination (95% Cl)
IPSS increase ≥ 4 points
AUR
Incontinence
UTI
Renal insufficiency
Figure 7 CombAT 4-year secondary endpoints – clinical progression.
Notes: Rate based on iTT population; *P , 0.001 versus combination. Reprinted 
with  permission  from  Roehrborn  CG,  Siami  P,  Barkin  J,  et  al.  The  effects  of 
combination therapy with dutasteride and tamsulosin on clinical outcomes in men 
with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT 
study. Eur Urol. 2010;57(1):123–131.19 Copyright © 2010 elsevier.
Abbreviations: AUR, acute urinary retention; BPH, benign prostatic hyperplasia; 
IPSS,  International  Prostate  Symptom  Score;  ITT,  intention-to-treat;  UTI,  urinary 
tract infection.
– 12 questions covering six areas 
– Control of urinary symptoms 
– Strength of urinary stream 
– Two aspects of pain of urination 
– Effect on usual activities 
– Overall satisfaction 
– Whether the respondent would ask their doctor for 
this medication 
Figure  8  Description  of  Patient’s  Perception  of  Study  Medicine  Questionnaire 
(PPSM).14
Note: Seven-point scale (Qs 1 to 11) or ‘yes’, ‘no’ or ‘not sure’ (Q12).
Satisfaction with treatment (Q11 of PPSM)
Desire to request study medication once trial over (Q12 
of PPSM)
Combination: 80% (P < 0.001 versus monotherapy)    
Combination group: 64% (P < 0.001 versus each 
monotherapy)    
Tamsulosin: 69%
Tamsulosin: 55%
Dutasteride: 74%
Dutasteride: 58%
Figure 9 Patient’s Perception of Study Medicine Questionnaire (PPSM) results for 
questions 11 and 12.Patient Preference and Adherence 2011:5 submit your manuscript | www.dovepress.com
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reported in either monotherapy arm would be less than, 
  additive, or greater in the combination arm was reported.
The only side effect for which the total in the combina-
tion arm was greater than the sum of the reported incidences 
in either monotherapy arm was in the complaint related to 
ejaculatory dysfunction. In this area the combination of the 
decreased volume associated with the 5 ARI, when added to 
either the retrograde ejaculation or diminished release from 
the seminal vesicles, was experienced and reported by the 
patients more in the combination arm than in the 2 mono-
therapy arms combined19 (Figure 10).
As was reflected in the PPSM, there was no significant 
difference in the “drug related adverse events leading to study 
withdrawal” rates in the 3 arms when comparing combination 
with dutasteride with tamsulosin. The reported rates were 6%, 
4%, and 4% respectively out of . 1600 patients in each arm.
It is also important to be able to inform the patients 
that drug-related adverse events diminished over time, the 
incidence being about 12% in the first year, but only 2% in 
the fourth year. Therefore, it is important to encourage the 
patients to stay on the drugs, because if they do not get side 
effects in the first year, the chances of experiencing side 
effects later on is greatly diminished.
Initiation and/or withdrawal of 
combination therapy
If there is concern about the economics or potential long-term 
side effects of combination therapy, there is information to 
suggest that in 77% of patients who received combination 
Adverse events
Drug-related adverse events
occurring in ≥ 1 of subjects
Erectile dysfunction 9
4
4
3
2
2
2
2
1
1
5
1
2
<1
2
1
<1
<1
<1
<1
7
<1
3
<1
<1
1
<1
2
<1
1
Retrograde ejaculation
Altered (decreased) libido
Ejaculation failure
Semen volume decreased
Loss of libido
Dizziness
Gynecomastia
Nipple pain
Breast tenderness
Combination
(n = 1610) %
Dutasteride
(n = 1623) %
Tamsulosin
(n = 1611) %
Figure 10 CombAT 4-year incidence of drug-related adverse events.
Note: Reprinted with permission from Roehrborn CG, Siami P, Barkin J, et al. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in 
men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol. 2010;57(1):123–131.19 Copyright © 2010 elsevier.
(dutasteride and tamsulosin) therapy for 6 months followed by 
alpha blocker withdrawal, felt the same or better 6 months after 
stopping the alpha blocker. If their original IPSS was .20, this 
favored response was reached in only 56% of the men.25
It is also important to consider that if combination therapy 
is going to be started, it should be initiated early (adding 
5ARI to alpha blocker) or simultaneously. For every month 
delay in adding the 5ARI, if a patient starts with alpha 
blocker monotherapy, a decrease in response of about 2%   
as measured at the end of 1 year.21
Conclusion
CombAT has clearly demonstrated that for the man with 
an enlarged prostate (.30 mL) and moderate symptom 
complaints, the combination of dutasteride and tamsulosin 
compared with monotherapy will provide the most effective 
and most durable long-term benefits. This was demonstrated 
in all parameters including symptom response, lack of progres-
sion, and the development of AUR or the need for surgery. 
  Moreover, the combination is safe with very few significant 
side effects or adverse events. Finally, if given the choice a 
greater number of patients would choose and continue to regu-
larly take the combination therapy over either monotherapy.
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